Cis Nonpres Image 01
Cisatracurium Besylate Injection
Product Images NDC 0781-3153
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Cisatracurium Besylate (NDC 0781-3153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Cis Nonpres Image 02
This appears to be a chart or graph with percentages and a label for "MAP". However, without more context or a visual representation, it is not possible to provide a useful description beyond that.*
Cis Nonpres Image 03
Cis Nonpres Image 04
Cisatracurium Besylate Injection is a medication used for intravenous injection to cause respiratory arrest in patients. It is a paralyzing agent, therefore facilitation for artificial respiration must be immediately available. Each mL of the injection contains 2 mg cisatracurium besylate. The usual dosage of the medication can be found in the package insert. It is recommended to refrigerate the injection at a temperature between 2-8°C (36 to 46°F), but not to freeze it. Once removed from the refrigerator, it should be used within 21 days. The medication is manufactured in India by Gland Pharma Limited for Sandaz e, Princeton, NJ.*
Cis Nonpres Image 05
Cisatracurium Besylate Injection is a paralyzing agent used for intravenous injection only. The injection is refrigerated and must be kept at 2° to 8°C to avoid freezing. Upon removal from refrigeration to room temperature, use within 21 days, even unrefrigerated. The injection is manufactured by Gland Pharma Limited in India for Sandoz, Inc. The package insert should be consulted for the usual dosage of the injection. The product is available in 200 mg/20 mL concentration, and each mL contains cisatracurium besylate equivalent to 10 mg of cisatracurium and water for Injection USP. The injection must be kept out of the reach of children. Facilities must be immediately available for artificial respiration.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
